A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
AstraZeneca ZD6474 Medical Science Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
D4200C00007
NCT00071188
February 2004
October 2007
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Arlington Heights, Illinois |
Research Site | Beverly, Massachusetts |
Research Site | Branson, Missouri |
Research Site | Pawtucket, Rhode Island |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |